Key Highlights

● BSX closed at $42.71 on 9 October 2026, and the second data set's $59.72 average target implies upside of about 39.8%.

● Market data shows a higher $66.31 average from 30 analysts, with targets from $48 to $118.

● The second data set counts 25 of 31 analysts at Buy or Strong Buy, while market data shows 22 Buy, six Hold and two Sell.

● Barclays moved to Hold with a $48 target on 7 October, and Citigroup, Wells Fargo and Barclays all sit at $48.

Boston Scientific Corporation (NYSE:BSX), the medical-device group, closed at $42.71 on Friday 9 October 2026. Analyst targets have been trimmed repeatedly since July, but the average forecast still sits well above the market price.

What Is the Latest Analyst Price Target?

The second data set, using third-party data last updated on 7 October 2026, reports an average 12-month price target of $59.72 and a median of $57, from 31 analysts. Against the $42.71 close on 9 October 2026, the consensus target suggests potential upside of about 39.8%. Individual forecasts range from $44 to $94.

Market data reports a higher average of $66.31 (about 55% implied upside) from 30 analysts, with a high of $118 and a low of $48. Its figures appear to include older targets set before the recent cuts.

What Are Wall Street Analysts Saying?

On the second data set's count, 25 of 31 analysts rate the shares Buy or Strong Buy, six rate them Hold and none Sell. Market data records 22 Buy, 6 Hold and 2 Sell ratings, with a consensus of Moderate Buy.

Recent broker actions include: Barclays upgraded the shares to Hold on 7 October 2026 with a $48 target; Citigroup lowered its target from $50 to $48 on 5 October 2026 with a Neutral rating; Bernstein reiterated Outperform on 3 October 2026 and cut its target from $60 to $54; J.P. Morgan maintained a Buy with a $56 target on 1 October 2026; RBC maintained a Buy with a $70 target on 1 October 2026; Wells Fargo lowered its target from $50 to $48 on 23 September 2026; Oppenheimer lowered its target from $85 to $65 on 21 September 2026; and BTIG lowered its target from $60 to $56 on 9 September 2026.

In late July 2026 UBS cut its target from $74 to $67, Baird set $56 and Leerink set $60.

What Could Help the Stock Reach the Price Target?

Market data reports the most recent quarterly results as earnings per share of $0.86 against $0.83 expected, and revenue of $5.44 billion against $5.38 billion expected, up 7.5% year on year. It also cites full-year 2026 earnings-per-share guidance of $3.28 to $3.32. Continued growth in line with those figures, and a sentiment recovery as the market digests the recent cuts, are the kind of developments that could narrow the gap to the consensus target. The large majority of brokers retain Buy-type ratings.

What Could Prevent the Stock Reaching the Target?

Targets have also been repeatedly lowered, with Citigroup, Wells Fargo and Barclays all at $48, which is only about 12% above the share price. Argus downgraded the stock to Hold on 31 July 2026, and market data lists two Sell-equivalent ratings. If estimates fall further or the recovery is slower than hoped, the shares could stay well below the consensus level.

What Should Investors Watch Next?

Watch for further broker revisions, and whether target cuts continue or stabilise.

Boston Scientific's Repeated Target Cuts Leave Averages Well Above the Price

Boston Scientific closed at $42.71 on 9 October 2026, with the second data set's $59.72 average target about 39.8% higher and market data's $66.31 higher still, though its figures appear to include older targets set before the recent cuts. Citigroup, Wells Fargo and Barclays now sit at $48, only about 12% above the share price, and Argus downgraded to Hold on 31 July. Yet the large majority of brokers retain Buy-type ratings, and market data shows full-year 2026 earnings-per-share guidance of $3.28 to $3.32.